Holosmedic
South Korean biomedical company developing 3D-printed biodegradable scaffolds and regenerative medical devices while also researching anticancer drug resistance treatments
- CEO / Founder
- YeoJin Yun (윤여진)
- Team Size
- 11-50
- Stage
- Active
Technology & Products
Key Products
Holosmedic Mesh (3D-printed biodegradable scaffold for craniomaxillofacial bone defect reconstruction); Earive (3D-printed neonatal ear correction splint); Drug-loaded scaffolds (under development); HLM2101 (anticancer drug resistance therapy, preclinical)
Technological Advantage
Proprietary 3D printing technology for biodegradable medical devices; end-to-end in-house capabilities (design, manufacturing, sales); HOLOSCOVERDY platform for anticancer drug resistance target discovery; GMP-certified manufacturing facility
Differentiation
Value Proposition
Develops 3D-printed, biodegradable medical implants (scaffolds/mesh) for craniomaxillofacial bone reconstruction and neonatal ear deformity correction, with a parallel oncology pipeline targeting drug resistance
How They Differentiate
Holosmedic differentiates by combining a novel drug discovery pipeline (anticancer resistance) with 3D-printed medical devices as a near-term revenue source, leveraging in-house design/manufacturing for cost advantage, and targeting the plastic surgery market specifically
Market & Competition
Target Customers
Hospitals and clinics (plastic surgery, craniomaxillofacial surgery, ENT) in South Korea and Southeast Asia
Industry Verticals
Medical Devices (Regenerative Medicine, Plastic Surgery, Craniomaxillofacial Surgery); Pharmaceuticals (Oncology)
Competitors
T&R Biofab (Korean 3D bioprinting scaffold company); Cellivera (Korean regenerative medicine company); 3D Medico (Korean medical 3D printing firm)
Growth & Milestones
Growth Metrics
Selected for Baby Unicorn 200 program by Korean Ministry of SMEs and Startups (H2 2022); First overseas regulatory approvals (Thai FDA, Vietnam) in 2026
Major Milestones
2018: Company founded; 2022: Started 3D bioprinting-based scaffold development; 2022 H2: Selected for Baby Unicorn 200 program; 2024: Announced regenerative medicine expansion strategy; 2025: Launched Earive (neonatal ear correction device); 2026: Holosmedic Mesh received Thai FDA approval; 2026: Received Vietnam medical device approval
Notable Customers
Major hospitals in South Korea applying Earive (neonatal ear correction device); distribution partnerships being established in Thailand and Vietnam